%A Huang Shaojiang %T Clinical observation of albumin bound paclitaxel plus bevacizumab as second line therapy in patients with advanced pancreatic cancer %0 Journal Article %D 2014 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2014.08.019 %P 620-623 %V 41 %N 8 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9455.shtml} %8 2014-08-15 %X ObjectiveTo investigate the efficacy, adverse reaction and survival condition of albuminbound paclitaxel combined with bevacizumab as secondline therapy in patients with advanced pancreatic cancer. MethodsTwentyseven cases of advanced pancreatic cancer were enrolled to receive albuminbound paclitaxel combined with bevacizumab regimen. The dose of the drugs was as follows: albuminbound paclitaxel 130 mg/m2, d1, bevacizumab 7.5 mg/m2, d1. Twentyone days were a cycle for each regimen, and the least chemotherapy cycle was 2. The adverse reactions were evaluated for each cycle and the objective response was evaluated for 2 cycles. ResultsThe 27 patients could be evaluated. None was in complete remission, 2 cases were in partial remission, 14 cases were in stabilization, 11 cases were in progress. The response rate (RR) was 7.41%, and the disease control rate (DCR) was 59.26%. The median progress free survival (PFS) was 4 months (95％CI: 3.0044.996 months), and the median overall survival (OS) was 8 months (95％CI: 5.90010.100 months). The main adverse reactions included myelosuppression, gastrointestinal reaction, fatigue, lipsotrichia, erythra, peripheral neurotoxicity, etc, most of which were 12 grade. The adverse effect was well tolerated, and there was no treatmentrelated death. ConclusionThe albuminbound paclitaxel combined with bevacizumab as secondline therapy in patients with advanced pancreatic cancer shows slow progress and low adverse effect and needs further study.